Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Angioedemas, Hereditary | 53 | 2023 | 91 | 15.420 |
Why?
|
Drug Hypersensitivity | 61 | 2024 | 923 | 14.000 |
Why?
|
Anaphylaxis | 29 | 2023 | 758 | 6.230 |
Why?
|
Angioedema | 17 | 2023 | 184 | 4.510 |
Why?
|
Skin Tests | 29 | 2024 | 639 | 4.170 |
Why?
|
Complement C1 Inhibitor Protein | 32 | 2023 | 97 | 4.140 |
Why?
|
Desensitization, Immunologic | 18 | 2024 | 558 | 3.520 |
Why?
|
Hypersensitivity | 12 | 2023 | 1172 | 2.620 |
Why?
|
Carboplatin | 7 | 2018 | 797 | 2.470 |
Why?
|
Hypersensitivity, Immediate | 9 | 2023 | 349 | 2.230 |
Why?
|
Plasma Kallikrein | 7 | 2023 | 21 | 2.120 |
Why?
|
Allergy and Immunology | 7 | 2020 | 175 | 1.980 |
Why?
|
Penicillins | 11 | 2024 | 406 | 1.760 |
Why?
|
Allergens | 14 | 2021 | 1443 | 1.730 |
Why?
|
Hereditary Angioedema Types I and II | 4 | 2022 | 10 | 1.720 |
Why?
|
Urticaria | 8 | 2022 | 151 | 1.610 |
Why?
|
Food Hypersensitivity | 11 | 2024 | 734 | 1.330 |
Why?
|
Anti-Bacterial Agents | 21 | 2024 | 7477 | 1.280 |
Why?
|
Hypersensitivity, Delayed | 4 | 2019 | 491 | 1.210 |
Why?
|
Pharmaceutical Preparations | 5 | 2021 | 1088 | 1.120 |
Why?
|
Platinum Compounds | 2 | 2017 | 95 | 1.080 |
Why?
|
Complement C1 Inactivator Proteins | 4 | 2016 | 89 | 1.010 |
Why?
|
Epinephrine | 7 | 2013 | 794 | 0.960 |
Why?
|
Cost of Illness | 5 | 2021 | 1951 | 0.950 |
Why?
|
Immunologic Tests | 2 | 2015 | 104 | 0.920 |
Why?
|
International Classification of Diseases | 4 | 2019 | 937 | 0.860 |
Why?
|
Bradykinin | 5 | 2018 | 205 | 0.820 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 8 | 2022 | 2271 | 0.810 |
Why?
|
Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2022 | 39 | 0.800 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 4 | 2017 | 1515 | 0.800 |
Why?
|
Quality of Life | 20 | 2024 | 13490 | 0.780 |
Why?
|
Antineoplastic Agents | 10 | 2024 | 13676 | 0.760 |
Why?
|
beta-Lactams | 3 | 2019 | 158 | 0.750 |
Why?
|
Humans | 194 | 2024 | 768166 | 0.730 |
Why?
|
Pruritus | 2 | 2022 | 379 | 0.730 |
Why?
|
Cephalosporins | 3 | 2019 | 200 | 0.730 |
Why?
|
Paclitaxel | 3 | 2021 | 1733 | 0.720 |
Why?
|
Home Infusion Therapy | 3 | 2016 | 18 | 0.720 |
Why?
|
Eosinophilia | 2 | 2023 | 556 | 0.660 |
Why?
|
Proton Pump Inhibitors | 2 | 2016 | 552 | 0.660 |
Why?
|
Emergency Service, Hospital | 17 | 2020 | 7951 | 0.650 |
Why?
|
Vaccines, Synthetic | 2 | 2021 | 622 | 0.630 |
Why?
|
Skin | 3 | 2021 | 4503 | 0.570 |
Why?
|
Anesthesia | 2 | 2020 | 1596 | 0.540 |
Why?
|
Organoplatinum Compounds | 2 | 2015 | 408 | 0.540 |
Why?
|
Immunization | 1 | 2021 | 1219 | 0.530 |
Why?
|
Cystadenoma, Serous | 1 | 2016 | 100 | 0.520 |
Why?
|
Vancomycin | 2 | 2016 | 506 | 0.500 |
Why?
|
Complement Inactivating Agents | 3 | 2018 | 53 | 0.490 |
Why?
|
Middle Aged | 66 | 2024 | 223492 | 0.490 |
Why?
|
Drug Prescriptions | 2 | 2015 | 1668 | 0.490 |
Why?
|
Influenza Vaccines | 1 | 2022 | 781 | 0.490 |
Why?
|
Female | 96 | 2024 | 397192 | 0.480 |
Why?
|
Dyspnea | 1 | 2022 | 1352 | 0.470 |
Why?
|
Disease Management | 8 | 2021 | 2536 | 0.450 |
Why?
|
2-Pyridinylmethylsulfinylbenzimidazoles | 1 | 2013 | 32 | 0.440 |
Why?
|
Vaccines | 1 | 2022 | 842 | 0.440 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2017 | 622 | 0.440 |
Why?
|
Serotonin 5-HT3 Receptor Antagonists | 1 | 2013 | 23 | 0.440 |
Why?
|
Respiratory Hypersensitivity | 1 | 2015 | 272 | 0.420 |
Why?
|
Edema | 3 | 2022 | 765 | 0.420 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2022 | 1642 | 0.420 |
Why?
|
Adult | 66 | 2024 | 223646 | 0.410 |
Why?
|
Male | 81 | 2024 | 364719 | 0.410 |
Why?
|
Ondansetron | 1 | 2013 | 95 | 0.410 |
Why?
|
Cisplatin | 1 | 2018 | 1660 | 0.410 |
Why?
|
Biological Products | 2 | 2021 | 948 | 0.400 |
Why?
|
Aged | 45 | 2024 | 171504 | 0.400 |
Why?
|
Length of Stay | 2 | 2024 | 6498 | 0.390 |
Why?
|
Intradermal Tests | 2 | 2023 | 43 | 0.390 |
Why?
|
Patient Satisfaction | 6 | 2020 | 3488 | 0.390 |
Why?
|
Patients | 1 | 2018 | 908 | 0.380 |
Why?
|
Injections, Subcutaneous | 6 | 2019 | 687 | 0.380 |
Why?
|
Anti-Asthmatic Agents | 1 | 2016 | 577 | 0.370 |
Why?
|
Education | 1 | 2014 | 533 | 0.370 |
Why?
|
Practice Guidelines as Topic | 11 | 2021 | 7454 | 0.360 |
Why?
|
Antibodies, Monoclonal | 2 | 2018 | 9263 | 0.360 |
Why?
|
Vaccination | 8 | 2022 | 3437 | 0.350 |
Why?
|
Ambulatory Care Facilities | 1 | 2016 | 939 | 0.340 |
Why?
|
Home Care Services | 1 | 2016 | 659 | 0.340 |
Why?
|
Pregnancy Complications | 3 | 2020 | 2973 | 0.340 |
Why?
|
Aspirin | 3 | 2022 | 3135 | 0.330 |
Why?
|
Electronic Health Records | 5 | 2023 | 4887 | 0.330 |
Why?
|
Outpatients | 4 | 2023 | 1600 | 0.330 |
Why?
|
United States | 32 | 2024 | 73039 | 0.320 |
Why?
|
Risk | 7 | 2019 | 9613 | 0.300 |
Why?
|
Complement C4 | 1 | 2009 | 216 | 0.300 |
Why?
|
Anti-Inflammatory Agents | 2 | 2016 | 1805 | 0.300 |
Why?
|
Histamine H1 Antagonists, Non-Sedating | 1 | 2007 | 17 | 0.290 |
Why?
|
Self Administration | 4 | 2018 | 386 | 0.290 |
Why?
|
Perioperative Care | 1 | 2015 | 1043 | 0.290 |
Why?
|
Diphenhydramine | 1 | 2007 | 63 | 0.280 |
Why?
|
Treatment Outcome | 26 | 2023 | 65371 | 0.280 |
Why?
|
Peptides | 4 | 2018 | 4354 | 0.280 |
Why?
|
Adrenal Cortex Hormones | 1 | 2016 | 1886 | 0.270 |
Why?
|
Young Adult | 21 | 2020 | 60066 | 0.270 |
Why?
|
Patient Education as Topic | 3 | 2016 | 2337 | 0.270 |
Why?
|
Cross Reactions | 3 | 2019 | 828 | 0.260 |
Why?
|
Retrospective Studies | 26 | 2024 | 81762 | 0.260 |
Why?
|
Adolescent | 32 | 2020 | 89169 | 0.250 |
Why?
|
Hospitalization | 7 | 2020 | 10840 | 0.250 |
Why?
|
Excipients | 2 | 2023 | 96 | 0.240 |
Why?
|
Cefazolin | 2 | 2016 | 95 | 0.230 |
Why?
|
Asthma | 4 | 2016 | 6291 | 0.230 |
Why?
|
Child | 31 | 2023 | 80917 | 0.230 |
Why?
|
Androgens | 2 | 2009 | 1281 | 0.220 |
Why?
|
Nasal Mucosa | 1 | 2007 | 416 | 0.220 |
Why?
|
Emergency Medical Services | 4 | 2016 | 1947 | 0.210 |
Why?
|
Rhinitis | 3 | 2008 | 753 | 0.210 |
Why?
|
Referral and Consultation | 4 | 2023 | 3620 | 0.210 |
Why?
|
False Negative Reactions | 2 | 2015 | 574 | 0.200 |
Why?
|
Algorithms | 3 | 2019 | 14164 | 0.200 |
Why?
|
Disease Progression | 10 | 2021 | 13671 | 0.200 |
Why?
|
Double-Blind Method | 8 | 2023 | 12465 | 0.200 |
Why?
|
Quality Improvement | 2 | 2018 | 3857 | 0.200 |
Why?
|
Child, Preschool | 19 | 2019 | 42669 | 0.200 |
Why?
|
Rosaniline Dyes | 1 | 2021 | 50 | 0.190 |
Why?
|
Diagnosis, Differential | 7 | 2022 | 13014 | 0.190 |
Why?
|
Pyrazoles | 2 | 2023 | 2028 | 0.190 |
Why?
|
Capillary Leak Syndrome | 1 | 2021 | 34 | 0.190 |
Why?
|
Nasal Polyps | 1 | 2007 | 412 | 0.190 |
Why?
|
Danazol | 4 | 2020 | 44 | 0.180 |
Why?
|
Internship and Residency | 1 | 2021 | 5953 | 0.180 |
Why?
|
Sinusitis | 2 | 2007 | 997 | 0.180 |
Why?
|
United States Food and Drug Administration | 2 | 2020 | 1673 | 0.170 |
Why?
|
Inpatients | 3 | 2018 | 2566 | 0.170 |
Why?
|
Ambulatory Care | 3 | 2023 | 2783 | 0.170 |
Why?
|
Ovarian Neoplasms | 2 | 2016 | 4916 | 0.170 |
Why?
|
Neoplasms | 3 | 2017 | 22371 | 0.170 |
Why?
|
Contraceptives, Oral, Combined | 1 | 2020 | 118 | 0.170 |
Why?
|
RNA, Messenger | 7 | 2022 | 12800 | 0.170 |
Why?
|
Age Factors | 6 | 2019 | 18412 | 0.170 |
Why?
|
Electronics, Medical | 1 | 2019 | 72 | 0.160 |
Why?
|
Physicians | 4 | 2021 | 4598 | 0.160 |
Why?
|
Infant | 11 | 2019 | 36535 | 0.160 |
Why?
|
Medical Records | 3 | 2015 | 1410 | 0.160 |
Why?
|
Complement System Proteins | 1 | 2022 | 738 | 0.160 |
Why?
|
Radiography, Abdominal | 1 | 2022 | 541 | 0.160 |
Why?
|
Perioperative Period | 2 | 2019 | 253 | 0.150 |
Why?
|
Consensus | 4 | 2023 | 3212 | 0.150 |
Why?
|
Lactation | 1 | 2020 | 392 | 0.150 |
Why?
|
Follow-Up Studies | 12 | 2021 | 39348 | 0.150 |
Why?
|
Immunoglobulin E | 4 | 2017 | 1506 | 0.150 |
Why?
|
Injections | 1 | 2021 | 840 | 0.150 |
Why?
|
Risk Assessment | 6 | 2022 | 24315 | 0.150 |
Why?
|
Aged, 80 and over | 12 | 2019 | 59629 | 0.150 |
Why?
|
Skull Fractures | 3 | 1987 | 203 | 0.140 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2021 | 737 | 0.140 |
Why?
|
Patient Acceptance of Health Care | 2 | 2023 | 3231 | 0.140 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2020 | 879 | 0.130 |
Why?
|
Respiratory Sounds | 1 | 2021 | 702 | 0.130 |
Why?
|
Hyaluronoglucosaminidase | 1 | 2016 | 138 | 0.130 |
Why?
|
Dermatitis | 1 | 2018 | 203 | 0.130 |
Why?
|
Drug Eruptions | 1 | 2019 | 335 | 0.130 |
Why?
|
Incidence | 5 | 2021 | 21538 | 0.130 |
Why?
|
Stevens-Johnson Syndrome | 2 | 2016 | 232 | 0.130 |
Why?
|
Tamoxifen | 1 | 2020 | 966 | 0.130 |
Why?
|
Antifibrinolytic Agents | 2 | 2016 | 289 | 0.130 |
Why?
|
Combined Modality Therapy | 2 | 2019 | 8542 | 0.130 |
Why?
|
Risk Factors | 12 | 2021 | 74944 | 0.130 |
Why?
|
Viral Vaccines | 1 | 2021 | 596 | 0.130 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2017 | 10760 | 0.120 |
Why?
|
Tuberculoma, Intracranial | 1 | 1995 | 8 | 0.120 |
Why?
|
Adenine | 1 | 2021 | 995 | 0.120 |
Why?
|
Lupus Erythematosus, Cutaneous | 1 | 2016 | 75 | 0.120 |
Why?
|
Prospective Studies | 13 | 2023 | 54926 | 0.120 |
Why?
|
India | 2 | 2021 | 2334 | 0.120 |
Why?
|
Pregnancy | 7 | 2022 | 30256 | 0.120 |
Why?
|
Nafcillin | 1 | 2014 | 23 | 0.120 |
Why?
|
Gene Deletion | 1 | 2022 | 2675 | 0.110 |
Why?
|
Seasons | 2 | 2010 | 1524 | 0.110 |
Why?
|
Oncology Service, Hospital | 1 | 2014 | 56 | 0.110 |
Why?
|
Methicillin | 1 | 2014 | 62 | 0.110 |
Why?
|
Breast Neoplasms | 1 | 2021 | 21206 | 0.110 |
Why?
|
Delayed Diagnosis | 1 | 2018 | 467 | 0.110 |
Why?
|
Boston | 6 | 2021 | 9374 | 0.110 |
Why?
|
Preventive Health Services | 1 | 2019 | 570 | 0.110 |
Why?
|
Factor XII | 1 | 2013 | 20 | 0.110 |
Why?
|
Estrogens | 1 | 2020 | 1536 | 0.110 |
Why?
|
Adrenergic Agonists | 1 | 2013 | 57 | 0.110 |
Why?
|
Insect Bites and Stings | 2 | 2012 | 72 | 0.110 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2021 | 951 | 0.110 |
Why?
|
Lymphoproliferative Disorders | 1 | 2017 | 528 | 0.110 |
Why?
|
Infusion Pumps | 1 | 2014 | 163 | 0.110 |
Why?
|
Astrocytoma | 3 | 1996 | 774 | 0.110 |
Why?
|
Physicians, Women | 1 | 2019 | 517 | 0.110 |
Why?
|
Bronchodilator Agents | 2 | 2007 | 518 | 0.100 |
Why?
|
Cross-Over Studies | 4 | 2023 | 2107 | 0.100 |
Why?
|
Autoantigens | 1 | 2017 | 890 | 0.100 |
Why?
|
Kallikreins | 1 | 2014 | 219 | 0.100 |
Why?
|
Schools, Medical | 1 | 2019 | 883 | 0.100 |
Why?
|
Menopause | 1 | 2020 | 1656 | 0.100 |
Why?
|
Piperidines | 1 | 2021 | 1667 | 0.100 |
Why?
|
Time Factors | 6 | 2021 | 40218 | 0.100 |
Why?
|
Cerebrospinal Fluid Shunts | 2 | 1992 | 197 | 0.100 |
Why?
|
Professional Practice | 1 | 2014 | 314 | 0.100 |
Why?
|
Infant, Newborn | 4 | 2018 | 26422 | 0.100 |
Why?
|
Costs and Cost Analysis | 1 | 2017 | 1667 | 0.100 |
Why?
|
Diagnostic Tests, Routine | 1 | 2017 | 789 | 0.100 |
Why?
|
Exanthema | 1 | 2016 | 503 | 0.100 |
Why?
|
Self Report | 3 | 2021 | 3773 | 0.090 |
Why?
|
Cytokines | 1 | 2006 | 7453 | 0.090 |
Why?
|
Neurofibroma | 1 | 1992 | 95 | 0.090 |
Why?
|
Receptors, Bradykinin | 1 | 2010 | 19 | 0.090 |
Why?
|
Preoperative Care | 1 | 2020 | 2258 | 0.090 |
Why?
|
Health Services Needs and Demand | 1 | 2019 | 1406 | 0.090 |
Why?
|
Faculty, Medical | 1 | 2019 | 1226 | 0.090 |
Why?
|
Natural Language Processing | 1 | 2019 | 1203 | 0.090 |
Why?
|
Shellfish | 1 | 2010 | 37 | 0.090 |
Why?
|
Remission Induction | 1 | 2016 | 2410 | 0.090 |
Why?
|
Brain Neoplasms | 6 | 1996 | 9118 | 0.090 |
Why?
|
Recurrence | 3 | 2022 | 8509 | 0.090 |
Why?
|
Back Pain | 1 | 2014 | 548 | 0.090 |
Why?
|
Recombinant Proteins | 2 | 2016 | 6514 | 0.090 |
Why?
|
Logistic Models | 3 | 2018 | 13290 | 0.090 |
Why?
|
Emergency Treatment | 1 | 2013 | 497 | 0.080 |
Why?
|
Spinal Cord Neoplasms | 1 | 1992 | 263 | 0.080 |
Why?
|
Virus Diseases | 1 | 2015 | 724 | 0.080 |
Why?
|
Food | 2 | 2012 | 768 | 0.080 |
Why?
|
Autoimmunity | 1 | 2017 | 1361 | 0.080 |
Why?
|
Diagnostic Errors | 1 | 2016 | 1281 | 0.080 |
Why?
|
Patient Preference | 1 | 2016 | 946 | 0.080 |
Why?
|
Clinical Trials as Topic | 3 | 2010 | 8054 | 0.080 |
Why?
|
Pyrimidines | 1 | 2021 | 3048 | 0.080 |
Why?
|
Nausea | 2 | 2022 | 682 | 0.080 |
Why?
|
Caregivers | 1 | 2021 | 2302 | 0.080 |
Why?
|
Oxymetholone | 1 | 2008 | 8 | 0.080 |
Why?
|
Stanozolol | 1 | 2008 | 3 | 0.080 |
Why?
|
Perception | 1 | 2015 | 1209 | 0.080 |
Why?
|
Autoantibodies | 1 | 2017 | 2121 | 0.080 |
Why?
|
Clinical Protocols | 2 | 2012 | 1443 | 0.070 |
Why?
|
Acute Disease | 3 | 2010 | 7243 | 0.070 |
Why?
|
Neurotoxins | 1 | 1989 | 240 | 0.070 |
Why?
|
Glycerol | 1 | 1989 | 274 | 0.070 |
Why?
|
Enzyme Inhibitors | 1 | 2018 | 3728 | 0.070 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 1993 | 498 | 0.070 |
Why?
|
Estrogen Antagonists | 1 | 2008 | 151 | 0.070 |
Why?
|
Central Nervous System Diseases | 1 | 1992 | 520 | 0.070 |
Why?
|
Chi-Square Distribution | 1 | 2013 | 3436 | 0.070 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 1995 | 1375 | 0.070 |
Why?
|
Pandemics | 3 | 2021 | 8748 | 0.070 |
Why?
|
Hematoma, Epidural, Cranial | 1 | 1987 | 59 | 0.070 |
Why?
|
Neurilemmoma | 1 | 1992 | 522 | 0.070 |
Why?
|
Mastoid | 1 | 1987 | 100 | 0.070 |
Why?
|
Embolism, Air | 1 | 1987 | 110 | 0.070 |
Why?
|
Severity of Illness Index | 4 | 2017 | 15948 | 0.070 |
Why?
|
Skin Diseases | 1 | 2015 | 1085 | 0.070 |
Why?
|
Quality Assurance, Health Care | 1 | 2016 | 2176 | 0.070 |
Why?
|
Odds Ratio | 2 | 2020 | 9669 | 0.060 |
Why?
|
Parturition | 1 | 2010 | 455 | 0.060 |
Why?
|
Phenotype | 3 | 2022 | 16726 | 0.060 |
Why?
|
Peak Expiratory Flow Rate | 1 | 2006 | 144 | 0.060 |
Why?
|
Dura Mater | 2 | 1987 | 293 | 0.060 |
Why?
|
Comorbidity | 2 | 2018 | 10590 | 0.060 |
Why?
|
Surgical Wound Infection | 2 | 1992 | 1546 | 0.060 |
Why?
|
Animals | 8 | 2021 | 169246 | 0.060 |
Why?
|
Capillary Permeability | 1 | 2009 | 772 | 0.060 |
Why?
|
Administration, Oral | 3 | 2020 | 4030 | 0.060 |
Why?
|
Meningioma | 2 | 1996 | 1220 | 0.060 |
Why?
|
Sciatic Nerve | 1 | 1989 | 628 | 0.060 |
Why?
|
Tomography, X-Ray Computed | 6 | 2022 | 20760 | 0.060 |
Why?
|
Hematoma | 1 | 1990 | 766 | 0.060 |
Why?
|
Bronchial Diseases | 1 | 2005 | 151 | 0.060 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 1995 | 3780 | 0.060 |
Why?
|
Chronic Disease | 3 | 2009 | 9384 | 0.060 |
Why?
|
Receptors, Chemokine | 1 | 2007 | 652 | 0.060 |
Why?
|
Premedication | 2 | 2017 | 246 | 0.060 |
Why?
|
Academic Medical Centers | 1 | 2014 | 2784 | 0.060 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2007 | 827 | 0.050 |
Why?
|
Meningeal Neoplasms | 1 | 1993 | 1253 | 0.050 |
Why?
|
Glioma | 3 | 1996 | 3503 | 0.050 |
Why?
|
Bacterial Infections | 1 | 1992 | 1397 | 0.050 |
Why?
|
Anxiety | 1 | 2018 | 4672 | 0.050 |
Why?
|
Bronchi | 1 | 2007 | 850 | 0.050 |
Why?
|
Guideline Adherence | 1 | 2013 | 2235 | 0.050 |
Why?
|
Hospitals, General | 2 | 2021 | 809 | 0.050 |
Why?
|
Quality of Health Care | 1 | 2018 | 4310 | 0.050 |
Why?
|
Chemotaxis, Leukocyte | 1 | 2005 | 660 | 0.050 |
Why?
|
Health Personnel | 1 | 2016 | 3385 | 0.050 |
Why?
|
Cross Infection | 1 | 1992 | 1426 | 0.050 |
Why?
|
Blood Transfusion | 1 | 1989 | 1309 | 0.050 |
Why?
|
Massachusetts | 1 | 2015 | 8890 | 0.050 |
Why?
|
Skull | 1 | 1987 | 820 | 0.050 |
Why?
|
Endothelium, Vascular | 2 | 1996 | 4427 | 0.050 |
Why?
|
Vitamin D Deficiency | 2 | 2010 | 1388 | 0.050 |
Why?
|
Reproducibility of Results | 3 | 2018 | 20227 | 0.050 |
Why?
|
Health Care Surveys | 2 | 2020 | 2434 | 0.050 |
Why?
|
Cardiovascular Agents | 2 | 2021 | 849 | 0.050 |
Why?
|
Cohort Studies | 4 | 2021 | 41754 | 0.050 |
Why?
|
Terbutaline | 1 | 2021 | 26 | 0.050 |
Why?
|
Sex Factors | 1 | 2015 | 10632 | 0.050 |
Why?
|
Telemedicine | 1 | 2019 | 3109 | 0.050 |
Why?
|
Neoplasm Staging | 1 | 2016 | 11244 | 0.050 |
Why?
|
Penicillin G | 1 | 2021 | 40 | 0.050 |
Why?
|
Tranexamic Acid | 2 | 2016 | 174 | 0.050 |
Why?
|
Theophylline | 1 | 2021 | 133 | 0.050 |
Why?
|
Prevalence | 4 | 2018 | 15869 | 0.050 |
Why?
|
Penicillanic Acid | 1 | 2021 | 41 | 0.050 |
Why?
|
Prognosis | 2 | 2015 | 30010 | 0.050 |
Why?
|
Predictive Value of Tests | 2 | 2014 | 15454 | 0.050 |
Why?
|
Infusions, Intravenous | 2 | 2017 | 2230 | 0.040 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2016 | 9419 | 0.040 |
Why?
|
Patient Discharge | 1 | 2013 | 3479 | 0.040 |
Why?
|
Dermatitis, Atopic | 1 | 2008 | 737 | 0.040 |
Why?
|
Syndrome | 1 | 2006 | 3272 | 0.040 |
Why?
|
Multivariate Analysis | 1 | 2013 | 12077 | 0.040 |
Why?
|
Serum Sickness | 1 | 2019 | 26 | 0.040 |
Why?
|
Basophil Degranulation Test | 1 | 2019 | 20 | 0.040 |
Why?
|
Intubation, Intratracheal | 1 | 2008 | 1359 | 0.040 |
Why?
|
Oral Hygiene | 1 | 2020 | 132 | 0.040 |
Why?
|
International Cooperation | 2 | 2018 | 1436 | 0.040 |
Why?
|
Malaria | 1 | 1989 | 1249 | 0.040 |
Why?
|
Vomiting | 1 | 2022 | 655 | 0.040 |
Why?
|
Pregnancy Trimesters | 1 | 2020 | 197 | 0.040 |
Why?
|
Personnel, Hospital | 1 | 2021 | 285 | 0.040 |
Why?
|
T-Lymphocytes | 2 | 2007 | 10266 | 0.040 |
Why?
|
Depression | 1 | 2018 | 8230 | 0.040 |
Why?
|
Nervous System Diseases | 1 | 1989 | 1662 | 0.040 |
Why?
|
Cerebral Hemorrhage | 1 | 1990 | 2655 | 0.040 |
Why?
|
Immunity, Humoral | 1 | 2022 | 610 | 0.040 |
Why?
|
Obesity | 2 | 2012 | 13090 | 0.040 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2019 | 330 | 0.040 |
Why?
|
Inflammation | 1 | 2017 | 10873 | 0.040 |
Why?
|
Expert Testimony | 1 | 2018 | 266 | 0.030 |
Why?
|
Endoscopy | 1 | 2007 | 1854 | 0.030 |
Why?
|
Plasma | 1 | 2020 | 585 | 0.030 |
Why?
|
Immunoglobulins, Intravenous | 1 | 2021 | 667 | 0.030 |
Why?
|
DNA Fingerprinting | 1 | 1996 | 114 | 0.030 |
Why?
|
Amoxicillin | 1 | 2017 | 182 | 0.030 |
Why?
|
Advisory Committees | 1 | 2020 | 797 | 0.030 |
Why?
|
Factor Analysis, Statistical | 1 | 2018 | 1001 | 0.030 |
Why?
|
Abdominal Pain | 1 | 2022 | 1070 | 0.030 |
Why?
|
National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2015 | 64 | 0.030 |
Why?
|
Diarrhea | 1 | 2022 | 1320 | 0.030 |
Why?
|
Haptens | 1 | 2015 | 163 | 0.030 |
Why?
|
Skin Diseases, Vesiculobullous | 1 | 2016 | 83 | 0.030 |
Why?
|
Lung Diseases | 1 | 2005 | 1944 | 0.030 |
Why?
|
Cell Movement | 1 | 2007 | 5210 | 0.030 |
Why?
|
Ultraviolet Rays | 2 | 2010 | 1103 | 0.030 |
Why?
|
Pregnant Women | 1 | 2020 | 576 | 0.030 |
Why?
|
Registries | 2 | 2022 | 8375 | 0.030 |
Why?
|
Hypotension | 1 | 2021 | 888 | 0.030 |
Why?
|
Dideoxynucleosides | 1 | 2015 | 135 | 0.030 |
Why?
|
Risk Adjustment | 1 | 2018 | 599 | 0.030 |
Why?
|
Nephritis, Interstitial | 1 | 2016 | 158 | 0.030 |
Why?
|
Policy | 1 | 2018 | 513 | 0.030 |
Why?
|
Case-Control Studies | 2 | 2024 | 22291 | 0.030 |
Why?
|
Carbamazepine | 1 | 2015 | 224 | 0.030 |
Why?
|
Drug Administration Schedule | 2 | 2013 | 4860 | 0.030 |
Why?
|
Congresses as Topic | 1 | 2018 | 812 | 0.030 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2019 | 1338 | 0.030 |
Why?
|
Brain Abscess | 2 | 1989 | 123 | 0.030 |
Why?
|
Isoantibodies | 1 | 2016 | 681 | 0.030 |
Why?
|
Denmark | 1 | 2015 | 776 | 0.030 |
Why?
|
Cefotaxime | 1 | 1992 | 36 | 0.020 |
Why?
|
Cephalexin | 1 | 1992 | 37 | 0.020 |
Why?
|
Antibodies, Neutralizing | 1 | 2022 | 2011 | 0.020 |
Why?
|
Cesarean Section | 1 | 2020 | 1425 | 0.020 |
Why?
|
DNA, Neoplasm | 1 | 1996 | 1744 | 0.020 |
Why?
|
Microscopy, Electron, Scanning | 1 | 1993 | 944 | 0.020 |
Why?
|
Gentamicins | 1 | 1992 | 244 | 0.020 |
Why?
|
Diagnosis, Computer-Assisted | 1 | 1996 | 709 | 0.020 |
Why?
|
Bee Venoms | 1 | 2010 | 23 | 0.020 |
Why?
|
Airway Management | 1 | 2014 | 326 | 0.020 |
Why?
|
Immunoglobulin G | 1 | 2022 | 4568 | 0.020 |
Why?
|
Bees | 1 | 2010 | 48 | 0.020 |
Why?
|
Injections, Intramuscular | 1 | 1992 | 556 | 0.020 |
Why?
|
Lumbosacral Region | 1 | 1992 | 294 | 0.020 |
Why?
|
Family | 1 | 2021 | 3209 | 0.020 |
Why?
|
HLA Antigens | 1 | 2015 | 1334 | 0.020 |
Why?
|
Microscopy, Electron | 1 | 1993 | 2560 | 0.020 |
Why?
|
Meningitis, Bacterial | 1 | 1992 | 225 | 0.020 |
Why?
|
Cranial Fossa, Posterior | 1 | 1990 | 134 | 0.020 |
Why?
|
Intention to Treat Analysis | 1 | 2010 | 416 | 0.020 |
Why?
|
Cell Division | 2 | 1996 | 4473 | 0.020 |
Why?
|
Hematoma, Subdural | 1 | 1990 | 128 | 0.020 |
Why?
|
Sunlight | 1 | 2010 | 337 | 0.020 |
Why?
|
Microcirculation | 1 | 1993 | 1281 | 0.020 |
Why?
|
Terminology as Topic | 1 | 2015 | 1542 | 0.020 |
Why?
|
Rats, Inbred Strains | 1 | 1989 | 2087 | 0.020 |
Why?
|
Nanotechnology | 1 | 2013 | 714 | 0.020 |
Why?
|
Receptors, CCR6 | 1 | 2007 | 73 | 0.020 |
Why?
|
Curriculum | 1 | 2020 | 3782 | 0.020 |
Why?
|
Computer Simulation | 1 | 2020 | 6283 | 0.020 |
Why?
|
Receptors, CXCR3 | 1 | 2007 | 240 | 0.020 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2015 | 2568 | 0.020 |
Why?
|
Fear | 1 | 2015 | 1495 | 0.020 |
Why?
|
Brain Damage, Chronic | 1 | 1987 | 265 | 0.020 |
Why?
|
Time | 1 | 2007 | 552 | 0.020 |
Why?
|
Activities of Daily Living | 1 | 2015 | 2430 | 0.020 |
Why?
|
Early Diagnosis | 1 | 2010 | 1194 | 0.020 |
Why?
|
Sex Distribution | 1 | 2010 | 2278 | 0.020 |
Why?
|
Patient Care Team | 1 | 2016 | 2523 | 0.020 |
Why?
|
Meninges | 1 | 1987 | 197 | 0.020 |
Why?
|
Bronchoalveolar Lavage Fluid | 1 | 2007 | 760 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2010 | 2923 | 0.020 |
Why?
|
Age Distribution | 1 | 2010 | 2873 | 0.010 |
Why?
|
Immunologic Factors | 1 | 2014 | 1596 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2010 | 2862 | 0.010 |
Why?
|
Smell | 1 | 2007 | 260 | 0.010 |
Why?
|
Cardiac Surgical Procedures | 1 | 2020 | 3683 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2020 | 14783 | 0.010 |
Why?
|
Interleukin-4 | 1 | 2007 | 1156 | 0.010 |
Why?
|
Genetic Testing | 1 | 2016 | 3591 | 0.010 |
Why?
|
Gene Expression | 1 | 2015 | 7598 | 0.010 |
Why?
|
Pregnancy Outcome | 1 | 2013 | 2972 | 0.010 |
Why?
|
Cysts | 1 | 1987 | 685 | 0.010 |
Why?
|
Cicatrix | 1 | 1987 | 798 | 0.010 |
Why?
|
Survival Rate | 2 | 1996 | 12840 | 0.010 |
Why?
|
Brain | 1 | 1987 | 27360 | 0.010 |
Why?
|
Seizures | 2 | 1990 | 2998 | 0.010 |
Why?
|
T-Lymphocyte Subsets | 1 | 2007 | 1815 | 0.010 |
Why?
|
Interferon-gamma | 1 | 2007 | 3160 | 0.010 |
Why?
|
Killer Cells, Natural | 1 | 2007 | 2211 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2019 | 26379 | 0.010 |
Why?
|
Critical Illness | 1 | 2010 | 2756 | 0.010 |
Why?
|
Health Services Accessibility | 1 | 2015 | 5520 | 0.010 |
Why?
|
Electrophoresis, Agar Gel | 1 | 1996 | 205 | 0.010 |
Why?
|
Vitamin D | 1 | 2010 | 3311 | 0.010 |
Why?
|
Deoxyribonucleases, Type II Site-Specific | 1 | 1996 | 167 | 0.010 |
Why?
|
Pilot Projects | 1 | 2010 | 8741 | 0.010 |
Why?
|
Blotting, Southern | 1 | 1996 | 775 | 0.010 |
Why?
|
DNA Probes | 1 | 1996 | 542 | 0.010 |
Why?
|
Evaluation Studies as Topic | 1 | 1996 | 1627 | 0.010 |
Why?
|
Rats | 1 | 1989 | 23760 | 0.010 |
Why?
|
Necrosis | 1 | 1996 | 1616 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2007 | 9538 | 0.010 |
Why?
|
Mitosis | 1 | 1996 | 1178 | 0.010 |
Why?
|
Observer Variation | 1 | 1996 | 2622 | 0.010 |
Why?
|
Pneumoencephalography | 1 | 1987 | 22 | 0.000 |
Why?
|
Magnetic Resonance Imaging | 1 | 1995 | 36743 | 0.000 |
Why?
|
Neovascularization, Pathologic | 1 | 1996 | 2631 | 0.000 |
Why?
|
Software | 1 | 1996 | 4478 | 0.000 |
Why?
|
Glioblastoma | 1 | 1996 | 3464 | 0.000 |
Why?
|
Heart Defects, Congenital | 1 | 1976 | 4712 | 0.000 |
Why?
|
Brain Diseases | 1 | 1987 | 1554 | 0.000 |
Why?
|
Chloramphenicol | 1 | 1976 | 67 | 0.000 |
Why?
|
Drainage | 1 | 1976 | 1183 | 0.000 |
Why?
|